Intuitive Surgical Inc
$ 467.22
1.80%
14 Apr - close price
- Market Cap 163,008,676,000 USD
- Current Price $ 467.22
- High / Low $ 471.24 / 459.50
- Stock P/E 58.47
- Book Value 50.19
- EPS 7.85
- Next Earning Report 2026-04-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.17 %
- 52 Week High 603.88
- 52 Week Low 427.84
About
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Analyst Target Price
$599.24
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-22 | 2025-10-16 | 2025-07-22 | 2025-04-22 | 2025-01-23 | 2024-10-17 | 2024-07-18 | 2024-04-18 | 2024-01-23 | 2023-10-19 | 2023-07-20 | 2023-04-18 |
| Reported EPS | 2.53 | 2.4 | 2.19 | 1.81 | 2.21 | 1.84 | 1.78 | 1.5 | 1.6 | 1.46 | 1.42 | 1.23 |
| Estimated EPS | 2.26 | 1.99 | 1.92 | 1.73 | 1.79 | 1.64 | 1.54 | 1.41 | 1.48 | 1.41 | 1.33 | 1.2 |
| Surprise | 0.27 | 0.41 | 0.27 | 0.08 | 0.42 | 0.2 | 0.24 | 0.09 | 0.12 | 0.05 | 0.09 | 0.03 |
| Surprise Percentage | 11.9469% | 20.603% | 14.0625% | 4.6243% | 23.4637% | 12.1951% | 15.5844% | 6.383% | 8.1081% | 3.5461% | 6.7669% | 2.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.63 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ISRG
2026-04-15 04:58:30
Intuitive Surgical maintains a strong lead in robotic-assisted surgery with its da Vinci systems, driven by a recurring revenue model from instrument sales and a growing installed base globally. The company's competitive edge comes from network effects, high switching costs for hospitals and surgeons, and continuous R&D. While facing competition and potential reimbursement risks, analysts generally view the stock positively due to its long-term growth trajectory and market dominance.
2026-04-14 21:12:11
Becton Dickinson (BD) is a leading medtech company with a strong position in essential healthcare tools, offering a resilient revenue mix across three segments: Medical, Life Sciences, and Interventional. Its business model, focused on consumables and innovation in essential healthcare fields, positions it as a defensive yet growth-oriented long-term holding. While facing risks like supply chain disruptions and competition, analysts view BD cautiously optimistically, citing its strong market moat, diversified portfolio, and consistent cash flow.
2026-04-14 16:08:03
Intuitive Surgical (ISIN: US46120E6023) maintains a dominant position in robotic-assisted surgery with its da Vinci Surgical System, which is crucial for minimally invasive procedures. The company relies on a recurring revenue model from instruments, accessories, and services, driving consistent growth. While facing increasing competition and regulatory scrutiny, analysts generally hold a bullish outlook due to its established market share, innovation in new applications like Ion, and global expansion in the healthcare sector.
2026-04-14 15:40:59
Intuitive Surgical (ISIN: US46120E6023) dominates the robotic-assisted surgery market with its da Vinci system, offering precise minimally invasive procedures and generating significant recurring revenue from instruments and services. The company's expansion into new applications like lung biopsies with its Ion system, coupled with innovation in AI and automation, strengthens its market position. Despite rising competition and potential pricing pressures, Intuitive's substantial market share, R&D investments, and strategic partnerships suggest continued growth, making it a key player for investors seeking exposure to advanced healthcare innovation.
2026-04-14 15:40:15
TELA Bio is advocating for case-specific approaches to hernia repair, urging medical professionals to discuss optimal solutions at the upcoming Intuitive Connect event. The company emphasizes that different hernia types, from inguinal to complex CAWR, necessitate varied products and surgical strategies. TELA Bio aims to utilize this platform to advance nuanced surgical decision-making and innovation in hernia treatments.
2026-04-14 15:20:06
Medtronic plc, a global leader in medical technology, offers investors exposure to healthcare innovation and demographic trends with its diversified portfolio across cardiovascular, medical surgical, neuroscience, and diabetes segments. The company demonstrates financial resilience with over $30 billion in annual revenue, strong free cash flow, and a consistent dividend growth record, positioning it well to capitalize on projected healthcare spending increases. Despite facing regulatory hurdles and intense competition, Medtronic's significant R&D investment and strategic acquisitions reinforce its competitive moat and long-term potential for shareholders.
